InVitae Corp (NVTA) Insider Sells $18,360.00 in Stock

InVitae Corp (NYSE:NVTA) insider Katherine Stueland sold 1,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $18.36, for a total value of $18,360.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Katherine Stueland also recently made the following trade(s):

  • On Tuesday, April 16th, Katherine Stueland sold 1,000 shares of InVitae stock. The stock was sold at an average price of $25.23, for a total value of $25,230.00.
  • On Friday, March 15th, Katherine Stueland sold 1,000 shares of InVitae stock. The stock was sold at an average price of $23.49, for a total value of $23,490.00.
  • On Wednesday, February 27th, Katherine Stueland sold 1,000 shares of InVitae stock. The stock was sold at an average price of $19.61, for a total value of $19,610.00.

Shares of NVTA stock traded down $0.26 during mid-day trading on Friday, hitting $18.05. 1,862,300 shares of the company’s stock were exchanged, compared to its average volume of 1,877,096. InVitae Corp has a fifty-two week low of $6.57 and a fifty-two week high of $26.77. The company has a quick ratio of 7.73, a current ratio of 7.73 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -9.30 and a beta of 2.20.

InVitae (NYSE:NVTA) last posted its quarterly earnings data on Tuesday, May 7th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). InVitae had a negative return on equity of 65.76% and a negative net margin of 81.52%. The business had revenue of $40.55 million for the quarter, compared to analyst estimates of $47.17 million. During the same quarter last year, the business earned ($0.66) EPS. InVitae’s revenue for the quarter was up 46.5% compared to the same quarter last year. As a group, analysts anticipate that InVitae Corp will post -1.97 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of NVTA. Bank of New York Mellon Corp boosted its holdings in shares of InVitae by 12.9% during the third quarter. Bank of New York Mellon Corp now owns 293,466 shares of the medical research company’s stock worth $4,910,000 after purchasing an additional 33,439 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in InVitae by 46.5% in the third quarter. JPMorgan Chase & Co. now owns 184,526 shares of the medical research company’s stock valued at $3,087,000 after acquiring an additional 58,538 shares during the last quarter. Morgan Stanley boosted its holdings in InVitae by 8.5% in the third quarter. Morgan Stanley now owns 152,712 shares of the medical research company’s stock valued at $2,555,000 after acquiring an additional 11,957 shares during the last quarter. Vanguard Group Inc. boosted its holdings in InVitae by 11.3% in the third quarter. Vanguard Group Inc. now owns 2,885,650 shares of the medical research company’s stock valued at $48,278,000 after acquiring an additional 292,125 shares during the last quarter. Finally, Vanguard Group Inc boosted its holdings in InVitae by 11.3% in the third quarter. Vanguard Group Inc now owns 2,885,650 shares of the medical research company’s stock valued at $48,278,000 after acquiring an additional 292,125 shares during the last quarter. Institutional investors and hedge funds own 67.56% of the company’s stock.

NVTA has been the subject of several recent research reports. Zacks Investment Research raised InVitae from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Wednesday, April 24th. Chardan Capital initiated coverage on InVitae in a research report on Monday, March 4th. They set a “buy” rating and a $29.00 price target for the company. Benchmark raised their price target on InVitae from $17.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, February 20th. Oppenheimer raised their price objective on InVitae from $21.00 to $30.00 and gave the stock an “outperform” rating in a report on Monday, April 8th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and set a $20.00 price objective on shares of InVitae in a report on Wednesday, February 20th. They noted that the move was a valuation call. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $25.00.

TRADEMARK VIOLATION WARNING: This piece was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/05/18/invitae-corp-nvta-insider-sells-18360-00-in-stock.html.

InVitae Company Profile

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.

Recommended Story: How is a buy-side analyst different from a sell-side analyst?

Insider Buying and Selling by Quarter for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.